AJP - Lung AJP: Renal Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 286: L1129-L1139, 2004; doi:10.1152/ajplung.00330.2003
1040-0605/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sumpter, T. L.
Right arrow Articles by Wilkes, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sumpter, T. L.
Right arrow Articles by Wilkes, D. S.

INVITED REVIEW

Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection

Tina L. Sumpter and David S. Wilkes

Departments of Medicine, Microbiology and Immunology, Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medicine Center, Indianapolis, Indiana 46202

Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-yr survival rates are worse for the lung than for any other transplanted organ. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survival. Therefore, these data suggest that other antigens, unrelated to donor transplantation antigens, are involved in rejection. Utilizing human and rodent studies of lung transplantation, our laboratory has documented that a native collagen, type V collagen [col(V)], is a target of the rejection response. Col(V) is highly conserved; therefore, these data indicate that transplant rejection involves both alloimmune and autoimmune responses. The role of col(V) in lung transplant rejection is described in this review article. In addition, the potential role of regulatory T cells that are crucial to modulating autoimmunity and alloimmunity is also discussed.

bronchiolitis obliterans; regulatory T cell; major histocompatibility complex



Address for reprint requests and other correspondence: D. S. Wilkes, Depts. of Medicine, Microbiology, and Immunology, Indiana Univ. School of Medicine, Richard L. Roudebush VA Medicine Center, 1481 W. 10th St. 111P, Indianapolis, IN 46202 (E-mail: dwilkes{at}iupui.edu).




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J. L. Bobadilla, R. B. Love, E. Jankowska-Gan, Q. Xu, L. D. Haynes, R. K. Braun, M. S. Hayney, A. Munoz del Rio, K. Meyer, D. S. Greenspan, et al.
Th-17, Monokines, Collagen Type V, and Primary Graft Dysfunction in Lung Transplantation
Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 660 - 668.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. S. Wilkes, T. M. Egan, and H. Y. Reynolds
Lung Transplantation: Opportunities for Research and Clinical Advancement
Am. J. Respir. Crit. Care Med., October 15, 2005; 172(8): 944 - 955.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.